Pancreatic Adenocarcinoma
287
59
95
97
Key Insights
Highlights
Success Rate
73% trial completion
Published Results
44 trials with published results (15%)
Research Maturity
97 completed trials (34% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
12.5%
36 terminated out of 287 trials
72.9%
-13.7% vs benchmark
5%
15 trials in Phase 3/4
45%
44 of 97 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 97 completed trials
Clinical Trials (287)
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in pt. w/ Metastatic PAC
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
Pancreatic Cancer Detection Consortium
Evaluation of XYA02 in Patients With Advanced Solid Tumors
9-ING-41 Combined With Retifanlimab, Plus Modified FOLFIRINOX for Patients With Advanced Pancreatic Adenocarcinoma (RiLEY)
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
Impact of Routine Electronic Patient-Reported Outcome (ePRO)Symptom Monitoring During Neoadjuvant Therapy in Patients withPancreatic Adenocarcinoma on Patient Experience and ClinicalOutcomes: A Prospective Pre-Post Implementation Study
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
Prehabilitation for EOC, Fallopian Tube, Primary Peritoneal Carcinoma and Pancreatic Cancer w/ NACT
Evaluating Novel Therapies in ctDNA Positive GI Cancers
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer
FOLFIRINOX + Elraglusib + Losartan In Pancreatic Cancer
Activation of Biobank Registry for Bilio-pancreatic Diseases
Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion